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Abstract
Background: The discovery of a solitary pulmonary nodule (SPN) on a chest imaging exam is of major clinical
concern. However, the incidence rates of SPNs in a general population have not been estimated. The objective of
this study was to provide incidence estimates of SPNs in a general population in 5 northeastern regions of France.
Methods: This population-based study was undertaken in 5 regions of northeastern France in May 2002-March 2003
and May 2004-June 2005. SPNs were identified by chest CT reports collected from all radiology centres in the study
area by trained readers using a standardised procedure. All reports for patients at least 18 years old, without a previous
history of cancer and showing an SPN between 1 and 3 cm, were included.
Results: A total of 11,705 and 20,075 chest CT reports were collected for the 2002–2003 and 2004–2005 periods,
respectively. Among them, 154 and 297 reports showing a SPN were included, respectively for each period. The
age-standardised incidence rate (IR) was 10.2 per 100,000 person-years (95% confidence interval 8.5–11.9) for
2002–2003 and 12.6 (11.0–14.2) for 2004–2005. From 2002 to 2005, the age-standardised IR evolved for men from 16.4
(13.2–19.6) to 17.7 (15.0–20.4) and for women from 4.9 (3.2–6.6) to 8.2 (6.4–10.0). In multivariate Poisson regression
analysis, gender, age, region and period were significantly associated with incidence variation.
Conclusions: This study provides reference incidence rates of SPN in France. Incidence was higher for men than women,
increased with age for both gender and with time for women. Trends in smoking prevalence and improvement in
radiological equipment may be related to incidence variations.
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Background
The discovery of a solitary pulmonary nodule (SPN) on
a chest imaging exam has been of major clinical concern
since the 1950s and has become common in current
clinical practice since the widespread use of computed
tomography (CT) [1–3]. Despite several studies on the
frequency of SPN discovered on imaging exams, inci-
dence data (number of new cases of SPN occurring
within a specified period of time among person-time at
risk in the population) are still scarce, especially in a
general population. In the 1950s, one SPN was found for
every 500 to 1000 chest radiographs in the USA,
depending on the population studied [4–6]. Since the
1990s, CT screening programs for lung cancer have been
providing estimates of the prevalence of non-calcified
nodules discovered in high-risk participants, but data on
the incidence of nodules, and especially SPNs, are
neither detailed enough nor even provided [7–11]. Fur-
thermore, they relate to groups at-risk and not to the
general population. Recently, a study among the Kaiser
Permanente Southern California member population
estimated that the incidence of incidental pulmonary
nodules of size 4–30 mm increased from 4.7 per 1,000
in 2008 to 5.4 in 2012 [12]. Despite the epidemiological
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and clinical relevance of these estimations, authors did
not distinguish SPNs from multiple nodules.
The lack of incidence data for SPNs may be explained
by the difficulty in obtaining non-biased data. Indeed,
SPNs represent multiple pathological entities, and their
assessment does not necessarily require a hospital stay
[13]. Therefore, unless a registration system of ambula-
tory care diagnosis has been set up, common sources of
medical information, such as health insurance or
hospital discharge data in France, fail to identify all
cases. Moreover, another difficulty in the identification
of incident cases is to ensure that the presence of the
nodule has not been noticed before. Nevertheless, inci-
dence data - measuring the speed of occurrence of a
pathology in the population - are useful to determine
the importance of this pathological entity in daily clinical
practice and to estimate human and material health care
resources needed. Finally, as the epidemiology of pul-
monary nodules evolves with imaging practices, a point
estimate of SPN incidence is essential to analyse future
trends [12].
This study aimed to estimate incidence rates of SPNs in
a general population in 5 northeastern regions of France
for two periods and to identify factors associated with dif-
ferences in incidence, using data collected within the
framework of a medico-economic evaluation program.
Methods
Study design and setting
This population-based study was undertaken in 5 contigu-
ous northeastern regions of France (Alsace, Bourgogne,
Champagne-Ardenne, Franche-Comté and Lorraine)
comprising 8,200,000 inhabitants and representing about
13% of the French population. This study is part of a lar-
ger medico-economic evaluation program that took place
from May 2002 to March 2003 and from May 2004 to
June 2005. This program was set up to analyse the conse-
quences of the implementation of positron emission tom-
ography (PET) cameras in France on the diagnostic and
therapeutic management of SPN and on other clinical
situations in oncology [14].
Participants
New SPN cases were identified from the analysis of CT
reports including the thorax and performed for various
reasons in current clinical practice. As a CT exam could
also include abdomen and pelvis besides thorax, these
reasons could be either pulmonary or non-pulmonary.
All radiological centres performing chest CT imaging
(community centres, as well as teaching, public or
private centres) participated for the 2 periods of the
study. Chest CT reports were collected in each centre
during 4 weeks (Lorraine) or 6 weeks (other regions)
in 2002–2003 and during 8 weeks in all regions in
2004–2005. The subperiods of data collection were
randomly assigned to each centre over the calendar
year to cover a continuous period of 10 and
15 months for each study period, respectively. Collec-
tion of CT reports was exhaustive over the designated
subperiods in each centre.
Reports for patients at least 18 years old with SPNs be-
tween 1 and 3 cm were included. Exclusion criteria were:
a nodule already known, reports for patients with a
current or past history of cancer (non-melanomatous
carcinomas excepted), a diagnostic procedure not per-
formed in the study area, spiculated or calcified SPN seen
on chest radiography and mentioned as such on the CT
report, multiple nodules, or ground glass opacities.
SPN report inclusion and data collection
In each region, a clinical research associate (CRA) was
in charge of collecting and analysing all reports of chest
CT. During ad-hoc sessions, the study investigators
trained CRAs to read the CT reports to ensure homoge-
neous results. An audit was carried out during each
study period to verify that the methods used by the
CRAs to collect data were in accordance with the opera-
tive procedures defined in the reference manual, which
contributed to the homogeneity of the results.
A CT report was eligible if it mentioned terms
suggesting the presence of a SPN (“nodule”, “spherical
lesion”, “round opacity”, “consolidation” etc.). For each
eligible report, information about a pre-existent nodule
was sought on the CT report, and checked in medical
records or by contact with the patient’s general practi-
tioner to ensure that the presence of the nodule had not
been noticed before. Only new cases were considered as
incident.
After CRAs selected a first round of eligible reports in
each region, all reports were pooled and reviewed by the
5 CRAs together. A report was included or excluded if
at least 4 CRAs agreed. Reports without agreement were
then reviewed by a panel of 5 physicians. These reports
were included or excluded if all physicians agreed.
Finally, reports remaining without agreement were
reviewed by the steering committee composed of the 5
physicians and the 5 CRAs who made the final decision
on inclusion. The inclusion procedure was identical for
both periods of the study.
The CRAs collected data on age, gender, history of
cancer and smoking, the referring physician for chest
CT, size category (1-3 cm versus < 1 or > 3 cm) and ap-
pearance (calcified or spiculated) of the nodule seen on
CT, and whether the SPN was discovered by chest radi-
ography or CT. They collected information on potential
development of lung cancer and vital status by telephone
contact with the patient’s physician 6 months after the
chest CT was performed.
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Statistical analysis
Annual French population data were provided by the
Institut national de la statistique et des études économi-
ques (INSEE).
For each study period, crude incidence rates were esti-
mated by gender, age group, region and for the whole
area covered by the 5 regions, by dividing the number of
new SPN cases by the sum of the person-times at risk in
the population over the study period. Incidence rates
were standardised to the world reference population [15]
by the direct method (to enable international compari-
sons). Estimations were based on the hypothesis of a
stationary population and a stable incidence rate of SPN
during the 2002-2005 period.
For crude and age-specific incidence rates, 95% confi-
dence intervals (95% CIs) were determined by the
Poisson distribution. For standardised incidence rates,
because usual conditions were met, a normal approxi-
mation was applied [16]. The binomial distribution was
used to determine 95% CIs for proportions. Fisher’s
exact test was used to compare the distribution of
cancer cases according to gender, period and histologic
subtypes. Poisson regression models including gender,
region, age-class and period were created to identify
factors related to variations in incidence rates (dummy
variables were used as appropriate). None of the interac-
tions included in the model was significant except for the
interaction between region and period. Thus, a stratified
Poisson regression model according to the period was
built. The SAS 9.2 statistical software was used for the
statistical analyses (SAS Inst., Cary, NC, USA).
The study protocol was approved by the institutional
review board in France, the Commission Nationale de
l’Informatique et des Libertés (CNIL) on January 2002.
Results
Participants
A total of 11,705 and 20,075 chest CT reports were ana-
lysed for the 2002–2003 and 2004–2005 periods, re-
spectively (Figs. 1 and 2). Overall, 233 (2.0%) and 418
(2.1%) reports, respectively, were considered eligible.
After exclusion of reports that did not meet the inclu-
sion criteria, 154 (1.3%) and 297 (1.5%) reports, respect-
ively, were included. Information about lung cancer
incidence and vital status at 6 months was collected for
125 (81%) and 240 (81%) patients, respectively.
Description of patients
Mean age (SD) at diagnosis was 65 (14) years (range 31–
92) in 2002–2003 and 64 (14) (range 22–90) in 2004–2005.
Overall, 73% and 65% were men for each period, respect-
ively (Table 1). Among subjects whose smoking status was
known (76% and 80%, respectively), 82% and 65% were
current or ex-smokers, respectively. For both periods, the
chest CT was prescribed by a specialised physician in ap-
proximately 70% of cases, otherwise by a general practi-
tioner. The presence of the SPN’s characteristic spiculated
or calcified was notified on chest CT reports for less than
half of the subjects (Table 1). In 2002–2003, nodules were
discovered equally by chest radiography or CT, whereas CT
was predominant in 2004–2005 (Table 1).
Incidence rates
The world age-standardised incidence rate was 10.2 per
100,000 person-years (95% CI 8.5–11.9) for 2002–2003
and 12.6 (11.0–14.2) for 2004–2005. Between 2002 and
2005, age-standardised rates evolved from 16.4 (13.2–
19.6) to 17.7 (15.0–20.4) for men and from 4.9 (3.2–6.6)
to 8.2 (6.4–10.0) for women (Table 2). For men, crude in-
cidence rates were 26.9 (22.1–32.3) new cases of SPN per
100,000 person-years in 2002–2003 and 28.2 (24.4–32.5)
in 2004–2005. For women, crude rates were 9.6 (6.9–13.0)
and 14.5 (11.9–17.6), respectively, for each period
(Table 2). In both genders, incidence increased with age,
and the increase was more marked in men than in women
(Fig. 3).
In multivariate analysis, no significant interaction
between gender and period was evidenced (p = 0.10).
However, when a Poisson regression model was stratified
according to gender, the period effect (2004–2005 vs
2002–2003) adjusted for age and region was significant
in women (incidence rate ratio [IRR] = 1.53, 95% CI
[1.07–2.19]) but not in men (IRR = 1.07, 95%CI [0.84–
1.34]). In both genders, incidence rates were significantly
related to age (p < 0.0001), but men aged 70 years or
more compared to men aged 50–59 years had a higher
IRR than their female counterparts (3.50 [2.25–5.44] vs
2.34 [1.50–3.64]).
Incidence also fluctuated among regions and on the
whole, incidence rates and IRR were higher in Alsace,
Champagne-Ardenne and Lorraine than in Bourgogne
and Franche-Comté (Tables 3 and 5). In multivariate ana-
lysis, incidence rates were significantly related to gender,
age, region and period by Poisson regression. A significant
qualitative interaction between region and period was
identified (p = 0.004). The estimated IRR for men versus
women was 3.47 (2.43–4.96) in 2002–2003 and 2.32
(1.83–2.95) in 2004–2005 (Table 4). For both periods, in-
cidence rates were significantly related to age and region
(Table 4).
Follow-up at 6 months
Six months after the inclusion of chest CT reports, 26%
(19%–35%) and 22% (17%–28%) of patients with avail-
able follow-up information showed lung cancer, respect-
ively for each period (Table 1). Lung cancer cases
increased for women in 2004–2005, albeit not signifi-
cantly (the ratio of males to females was 4.8 and 2.8 for
Marrer et al. BMC Cancer  (2017) 17:47 Page 3 of 11
2002–2003 and 2004–2005, p = 0.44). Nodules in cancer
patients were less calcified and more frequently discov-
ered by chest radiography than CT. These patients were
more often current or ex-smokers.
Squamous cell carcinoma represented the major type
of lung cancer in each period (49 and 42%, respectively),
followed by adenocarcinoma (36 and 34%, respectively).
This distribution was similar between the 2 periods (p =
0.71) (Table 5). Among all SPN cases, 24 and 26 patients
(16 and 9%), respectively, died within 6 months.
Discussion
This population-based study provides incidence esti-
mates of SPNs in a general population from 5 northeast-
ern regions of France. Age-standardised incidence rates
of SPNs were higher for men than women for the 2
periods and increased with age. Incidence also increased
with time, significantly for women but not for men. As a
comparison, the age-standardised incidence rate of SPNs
in 2004–2005 was similar to that of bladder cancer in
men (14.6) and ovarian cancer in women (8.1) [17].
Fig. 1 Flow-chart of CT reports analysed in 2002–2003
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Despite the lack of information on a possible relationship
between smoking and the occurrence of pulmonary nod-
ules, the higher incidence in men compared with women
may reflect the more widespread use of tobacco among
men. Indeed, although the prevalence of smoking has been
increasing among women since the 1950s in France [18],
until now, there were many more smokers among men
than women [19]. Moreover, the incidence of lung cancer is
higher for men than women [17]. As a result, clinicians
might more easily prescribe a chest imaging exam such as a
radiography or a CT for men than women, which might
explain the higher detection rate of SPN in men. However,
even if lung cancer incidence is higher for men than
women, the incidence has been constantly increasing for
women between 1980 and 2005 [17]. This trend could ex-
plain the significant increase in incidence in women be-
tween the two study periods. Indeed, the prescription of a
chest CT for women could have been more frequent in
2005 than in 2002. However, in the recent study of Gould,
incidence was slightly higher for women than men [12].
Several medical societies or physician working groups
have produced guidelines on management strategies for
Fig. 2 Flow-chart of CT reports analysed in 2004–2005
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incidental SPNs or non-small-cell lung cancer, but no
consensus has been reached [20–26]. Nevertheless,
worldwide and over time, a chest CT has been recom-
mended to identify or characterize pulmonary nodule(s).
Because no specific guidelines on SPN management
exist in France, and because guidelines did not change
between the two study periods, the increase in SPN inci-
dence attributable to changes in medical practice is
certainly small. Finally, because PET cannot be
substituted for CT, the implementation of PET between
the two periods certainly did not influence CT prescrip-
tion practice. It is also unlikely that the implementation
of PET would have impacted the evolution of SPN
incidence rates.
However, after a delay in the development of medical
imaging in France in comparison with other European
countries such as Germany, the French government edi-
ted recommendations for the development of CT and
magnetic resonance imaging (MRI) imaging in 2002
[27], that led to quantitative and qualitative improve-
ment in the following years and could explain at least in
part the increase in incidence of SPN we observed
between these two periods. Indeed, from December
2003 by December 2005, the number of CT devices
raised from 629 to 781 in France, representing an in-
crease of 24% [28]. Despite no comparable data were
available, neither for 2001 nor for 2002, we can deduce
that the quantitative increase in CT equipment between
the two study periods was superior to 25%.
In the same way, variations in human and material
resources in medical imaging such as the density of radi-
ologists or imaging devices could influence the prescrip-
tion of such exams and partly account for the observed
variability in incidence between regions. Actually by the
end of 2003 and 2005, the two regions with the lowest
SPN incidence rates, Bourgogne and Franche-Comté,
had also the lowest density of radiologists, of CT devices
and of imaging proceedings [29]. However, this could
only partly account for the variation observed because
Lorraine, for which the density of these indicators was
also very low, yet had the highest SPN incidence rate.
Screening programs, despite providing recent valuable
information, are limited in studying the incidence of
SPNs. First, they target at-risk populations, mostly
smokers aged 50 years and older. Second, the popula-
tions under study as well as the reporting of the results
are fairly heterogeneous among studies. Indeed, inci-
dence data for pulmonary nodules, especially SPNs, are
not straightforward. Nevertheless, some data may be
used to estimate the proportion of new, non-calcified
nodules identified among all subjects screened by chest
CT in 1 year. Thus, the incidence of non-calcified nod-
ules was found to vary from 1% per year for new
nodules ≥ 10 mm among smokers ≥ 60 years old in the
Table 1 Characteristics of patients and nodules
2002–2003 2004–2005
n = 154 n = 297
n % n %
Patients
Age
≥ 50 years 127 82.5 245 82.5
Gender
Men 112 72.7 193 65.0
Women 42 27.3 104 35.0
Region
Alsace 32 20.8 79 26.6
Bourgogne 18 11.7 36 12.1
Champagne-Ardenne 32 20.8 43 14.5
Franche-Comté 24 15.6 27 9.1
Lorraine 48 31.1 112 37.7
Smoking
Current or ex-smokers 96 82.1 154 64.7
Non smokers 21 17.9 84 35.3
No information 37 59
Referring physician for CT
General practitioner 41 29.1 89 30.0
Specialist 100 70.9 208 70.0
No information 13 0
Solitary pulmonary nodule
Spiculation
Yes 49 81.7 55 37.9
No 11 18.3 90 62.1
No information 94 152
Calcification
Yes 13 33.3 54 36.5
No 26 66.7 94 63.5
No information 115 149
Discovered by
Chest radiography 79 53.4 101 35.2
Chest CT 69 46.6 186 64.8
No information 6 10
Follow-up at 6 months
Cancer
Yes 33 26.4 53 22.1
No 92 73.6 187 77.9
No information 29 57
Death
Yes 24 15.6 26 8.8
No 130 84.4 271 91.2
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New-York ELCAP study [10], to 2% per year for nod-
ules > 5 mm in an Italian study of smokers ≥ 50 years
[30]. In two other studies, the incidence rate of new
non-calcified nodules ranged from 1.1 to 1.3% per year
for smokers older than 50 [31, 32]. However, these pro-
portions cannot be compared easily because screening
programs recruit asymptomatic subjects, whereas in the
present study, cases were recruited by current clinical
practice procedures, which may involve both asymptom-
atic and symptomatic subjects referred to the radiologist.
Finally, the study of Gould estimated that the incidence
of incidental pulmonary nodules of size 4–30 mm
increased from 2008 to 2012 [12]. However, although
the source of CT exams was current clinical practice as
in our study, the comparison is hampered by several fac-
tors: a larger nodule size definition, the identification of
nodules on CT reports by a natural language processing
algorithm that does not allow the distinction between
solitary and multiple nodules, a different definition of in-
cident nodules (no previous scan with pulmonary
nodule(s) within the previous 2 years), and finally a
different standard population used to report incidence
data (US population 2010). These factors could partly
explain the higher incidence reported in this Kaiser
Permanente study.
The proportion of malignancies observed at 6 months
was consistent with other published data. This probabil-
ity varies considerably among studies, depending on the
patient and nodule selection criteria (lung cancer risk
factors, current clinical practice or surgical series) and
the referral pattern of the study centre. In retrospective
cohorts of SPN, it ranged from 23% (newly discovered
SPN at the Mayo Clinic) to 58% (patients referred for
fluorodeoxyglucose - positron emission tomography
scanning) [33, 34]. In lung cancer screening studies, this
Table 2 Interregional incidence rates per 100,000 person-years by age, gender and period
Men Women
2002–2003 2004–2005 2002–2003 2004–2005
Person-years 416,926 683,299 437,200 716,751
IRa 95% CIb IRa 95% CIb IRa 95% CIb IRa 95% CIb
IRa by age group (years) 20–25 0.0 0.0 – 10.8 0.0 0.0 – 6.5 0.0 0.0 – 11.1 2.3 0.1 – 12.6
25–30 0.0 0.0 – 11.2 9.6 2.6 – 24.6 0.0 0.0 – 11.4 9.8 2.7 – 25.2
30–35 6.6 0.8 – 23.7 6.2 1.3 – 18.2 0.0 0.0 – 10.0 2.1 0.1 – 11.7
35–40 12.8 3.5 – 32.8 8.0 2.2 – 20.6 0.0 0.0 – 9.7 2.0 0.1 – 11.3
40–45 13.0 3.5 – 33.3 5.9 1.2 – 17.4 19.2 7.1 – 41.9 7.9 2.1 – 20.1
45–50 22.9 9.2 – 47.2 26.3 14.0 – 45.0 3.2 0.1 – 18.0 15.8 6.8 – 31.2
50–55 45.3 24.7 – 75.9 30.3 17.0 – 50.0 9.8 2.0 – 28.7 24.1 12.5 – 42.1
55–60 33.7 14.5 – 66.3 48.6 30.4 – 73.5 8.5 1.0 – 30.8 22.3 10.7 – 41.0
60–65 53.6 25.7 – 98.5 86.0 56.1 – 125.9 15.4 3.2 – 45.1 35.3 17.6 – 63.2
65–70 67.3 34.8 – 117.6 90.0 58.8 – 131.9 14.6 3.0 – 42.6 18.2 6.7 – 39.6
70–75 136.7 85.7 – 207.0 114.1 77.0 – 162.9 52.6 26.3 – 94.2 23.6 10.2 – 46.6
>75 127.1 85.1 – 182.5 118.3 86.9 – 157.3 31.0 16.5 – 53.0 53.0 37.5 – 72.8
Crude rate 26.9 22.1 – 32.3 28.2 24.4 – 32.5 9.6 6.9 – 13.0 14.5 11.9 – 17.6
Standardised IRc 16.4 13.2 – 19.6 17.7 15.0 – 20.4 4.9 3.2 – 6.6 8.2 6.4 – 10.0
aIR incidence rate
b95% CI: 95% confidence interval (Poisson exact CI for IR by age group and crude rates, normal approximation for standardised IR)
cStandardised IR: on the world reference population [15]
Fig. 3 Incidence rates of SPNs for 5 regions in northeastern France
for 2002-2003 and 2004-2005 by gender and age
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proportion is weaker and varies from 3 to 21%, which is
not surprising given that the underlying population is an
asymptomatic one [7]. The proportion observed in the
present study is intermediate, which is consistent with a
recruitment from a general population subjected to
current clinical procedures.
The distribution of histologic subtypes of lung cancer
we observed was consistent with results of a French
study showing that 40% of lung cancers were squamous
cell carcinomas and 30% were adenocarcinomas, as well
as with the results of an international study [35, 36].
One strength of the present study is that the collection
of CT reports was exhaustive, standardised, and per-
formed by specially trained CRAs. Moreover, this study
was managed by an interregional steering committee.
Although SPNs were included on the basis of CT
reports, the number of SPNs discovered by another
imaging exam that would not have led to a CT evalu-
ation can be considered negligible. However, the SPN
identification method based on the analysis of reports is
less reliable than an analysis of radiological images.
Some limitations should be mentioned. First, the
medico-economic evaluation program on which the
present study was based focused on indeterminate nod-
ules (for which malignancy is not foreseeable) because of
the highest diagnostic benefit of PET in this category of
nodules. Thus, subcentimetric nodules were not consid-
ered, as the probability of malignancy for these small
nodules is much lower than for larger ones; conse-
quently, clinical implications were quite different [23,
37]. In the same way, nodules that appeared spiculated
or calcified on chest radiography, or ground-glass opaci-
ties, were excluded as the associated probability of
malignancy is high. As a result, comparisons with other
data should be made with caution.
Second, the population investigated was the general
population subjected to current clinical practice procedures.
As a result, subjects with asymptomatic SPNs who did not
have any other reason to seek medical advice might not
have been identified in the study. Indeed, these subjects
may only be identified by a screening procedure. However,
it would be ethically unacceptable to ask asymptomatic
subjects, without any particular risk, to undergo CT or
similar exams, only to ensure that no case of SPN would be
missed in an epidemiologic study, given the uncertain bene-
fits of such a procedure. Consequently, the incidence of
SPNs can be considered slightly underestimated in this
respect. Nevertheless, our study had the capacity to recruit
subjects in a large variety of clinical situations and diagnos-
tic pathways (symptomatic as well as asymptomatic,
pulmonary as well as non-pulmonary, in the ambulatory
setting as well as the framework of hospital care) and
reasonably reflects the reality of daily clinical practice in
northeastern France. Furthermore, we think that this point
represents a strength rather than a weakness. However,
detailed clinical indications for CT were not collected. This
information would have been interesting to interpret the re-
sults because some infectious disease (particularly fungi in-
fections) may increase the incidence of nodules.
Third, some data about smoking status and nodule
characteristics could not be retrieved. Indeed, smoking
status is not systematically mentioned on CT reports or
in medical records, and is sometimes difficult to obtain
retrospectively from the patient’s practitioners. More-
over, in the absence of clear guidelines concerning the
reporting of imaging exams in France, CT reports are
heterogeneous. However, we may be confident that a
positive sign such as the presence of a calcification or a
spiculation would always be mentioned on a CT report.
Conversely, a negative sign, such as the absence of a
Table 3 Incidence rates per 100,000 person-years by region, gender and period
Alsace Bourgogne Champagne-Ardenne Franche-Comté Lorraine
IRa 95% CIb IRa 95% CIb IRa 95% CIb IRa 95% CIb IRa 95% CIb
Men
2002–2003 Crude rate 22.0 13.8–33.3 12.2 6.1–21.8 29.2 18.3–44.3 26.5 15.4–42.4 45.9 32.8–62.5
Standardised IRc 14.9 8.5–21.3 6.0 2.1–9.9 19.1 10.8–27.4 16.8 8.6–25.0 27.9 18.9–36.9
2004–2005 Crude rate 37.0 27.5–48.8 20.7 13.4–30.6 28.0 18.6–40.5 10.5 6.0–17.0 42.4 33.3–53.2
Standardised IRc 24.3 17.3–31.3 12.9 7.6–18.2 17.1 10.2–24.0 6.3 3.0–9.6 27.5 20.9–34.1
Women
2002–2003 Crude rate 9.6 4.6–17.6 7.3 2.9–15.0 12.7 6.1–23.3 10.5 4.2–21.7 8.8 3.8–17.3
Standardised IRc 5.4 1.8–9.0 3.6 0.6–6.6 6.3 1.8–10.8 6.6 1.3–11.9 3.6 0.7–6.5
2004–2005 Crude rate 20.5 13.7–29.4 8.5 4.3–15.3 14.2 8.0–23.5 6.9 3.5–12.4 20.8 14.7–28.5
Standardised IRc 12.1 7.1–17.1 3.7 1.0–6.4 8.5 3.4–13.6 3.8 1.1–6.5 12.4 8.0–16.8
aIR: incidence rate
b95% CI: 95% confidence interval (Poisson exact CI for IR by age group and crude rates, normal approximation for standardised IR)
cStandardised IR: on the world reference population [15]
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radiological abnormality, might not be systematically
mentioned. However, this limitation is not likely to sig-
nificantly affect our results.
Finally, length of follow-up was only 6 months,
which did not allow to determine the long-term
frequency of subsequent cancer diagnosis. However,
subjects for whom no information about a subsequent
malignant evolution was available did not show any
significant difference with respect to gender, age,
spiculation or calcification of the nodule on CT, or
vital status.
Conclusions
This study provides reference incidence rates of SPN in
the French general population. Incidence was higher for
men than women and increased with age. Moreover,
incidence increased between 2002 and 2005, significantly
for women but not for men. These differences seem to
reflect, at least in part, trends in tobacco consumption
as well as improvement in radiological equipment during
the study period.
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